Injectable Drugs and Other Specialty Pharmaceuticals
A Panel Discussion among Four Medical Directors and Four Pharmacy Directors
Price $2500
Deliverable: Discussion with key findings.
Study Description and Objectives:
To conduct a panel discussion among medical directors and pharmacy directors to understand trends in how injectable drugs and other specialty pharmaceuticals are being covered, and to assess the overall impact of these drugs on the cost of care for both commercial plans and Medicare.
§ Understand how many beneficiaries typically use specialty pharmaceuticals
§ Identify the impact specialty pharmaceuticals have on a plan’s overall costs
§ Assess any differences in coverage between specialty pharmaceuticals and traditional drugs
§ Discuss current practices for covering high-priced specialty pharmaceuticals
§ Examine measures used to manage the cost of specialty pharmaceuticals
§ Review patient responsibilities for covering cost of treatments
§ Estimate prevalence of so-called tier 4 copayments
§ Identify range of patient burdens for tier 4 copayments
§ Discuss and identify future trends for coverage of specialty pharmaceuticals including likely penetration of tier 4 structures and their impact
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
Genzyme |
GENZ |
Cerezyme® |
Inclusion Criteria and Panel Details:
|
Inclusion Criteria |
§ US-based medical or pharmacy directors § With their plan for over 2 years § Plans with high volume (>1mm beneficiaries) of covered lives § Plans must have at least one plan offered with tier 4 co-payments |
|
Discussion Dates |
July 9, 2008 through July 22, 2008 |
To purchase this report or request additional information, contact:Bottom of Form
Print Abstract
For additional information on this study or to purchase, please call:
|
Discussion
Other |